EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSONIG00000015587
Gene Symbol: PSMD13
4 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSONIG00000003332
Gene Symbol: PSMD14
4 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSONIG00000010770
Gene Symbol: PSMD2
4 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSONIG00000020359
Gene Symbol: PSMD6
4 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSONIG00000014838
Gene Symbol: PSMD7
4 Cross references
235 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSONIG00000004059
Gene Symbol: PSMD8
1 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSONIG00000038039
Gene Symbol: LOC100691978
4 Cross references
278 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSONIG00000003130
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11

Ensembl ID : ENSONIG00000029853
Gene Symbol: LOC100698550
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-5

Ensembl ID : ENSONIG00000015536
Gene Symbol: LOC100710977
3 Cross references
203 Possible Orthologues:

Proteasome Subunit Beta Type-7

Ensembl ID : ENSONIG00000011604
Gene Symbol: LOC100705995
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSONIG00000020043
Gene Symbol: LOC100696839
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).